- Home
- CREV vs ENVB Comparison
CREV vs ENVB Comparison
Compare CREV & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CREV | ENVB |
|---|---|---|
| Founded | 2007 | 1994 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1M | 3.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CREV | ENVB |
|---|---|---|
| Price | $0.40 | $2.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $120.00 |
| AVG Volume (30 Days) | 53.2K | ★ 66.7K |
| Earning Date | 01-30-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $47,677,475.00 | N/A |
| Revenue This Year | $40.32 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 86.77 | N/A |
| 52 Week Low | $0.36 | $2.04 |
| 52 Week High | $9.20 | $54.00 |
Technical Indicators
Market Signals| Indicator | CREV | ENVB |
|---|---|---|
| Relative Strength Index (RSI) | 17.50 | 26.81 |
| Support Level | $1.58 | $2.04 |
| Resistance Level | $1.65 | $4.67 |
| Average True Range (ATR) | 0.11 | 0.28 |
| MACD | -0.09 | -0.11 |
| Stochastic Oscillator | 2.87 | 3.19 |
Price Performance
Historical ComparisonAbout CREV Carbon Revolution Public Limited
Carbon Revolution PLC is an Australian-based technology company manufacturing carbon fiber wheels. It is an OEM supplier and a world-wide manufacturer of lightweight technology carbon fibre wheels to the automotive industry. The Company supplies wheels to OEMs across the globe for luxury and high-performance vehicles and SUVs, and is developing wheels for electric vehicles under contract for its OEM customers. The company generates maximum revenue Internationally.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.